Radiation Oncology Journal最新文献

Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement 局部晚期直肠癌伴直肠系膜筋膜受累者接受新辅助化放疗和全直肠系膜切除术的临床疗效

Radiation Oncology Journal Pub Date : 2024-06-12 DOI: 10.3857/roj.2023.01032

Jeong Ha Lee, Na-Young Kim, J. Yu, G. Yoo, Hee Chul Park, Woohyun Lee, S. Yun, H. Kim, Y. Cho, J. Huh, Y. Park, Jungwook Shin, Joon Oh Park, Seung-Tae Kim, Young Suk Park, Jeeyun Lee, Won-Ki Kang

引用次数: 0

Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 2. Lung (non-small cell lung cancer) 基于证据的超分割放射治疗临床建议：疗效与安全性探讨--第二部分。肺（非小细胞肺癌）

Radiation Oncology Journal Pub Date : 2024-06-10 DOI: 10.3857/roj.2023.00955

Y. Kwak, Kyung Su Kim, Gyu Sang Yoo, H. K. Byun, Yeon Joo Kim, Y. Kim, Soo-Yoon Sung, J. Song, Byoung Hyuck Kim

引用次数: 0

Analysis of risk factors for disease progression after salvage radiation therapy with androgen deprivation therapy in prostate cancer patients who have prostate-specific antigen persistence after radical prostatectomy 根治性前列腺切除术后前列腺特异性抗原持续存在的前列腺癌患者接受雄激素剥夺疗法的挽救性放射治疗后疾病进展的风险因素分析

Radiation Oncology Journal Pub Date : 2024-06-05 DOI: 10.3857/roj.2023.00962

Kyeonghyo Lee, Dongchan Kim, J. Nam, D. Park, Wontaek Kim, J. Joo, H. Jeon, Y. Ki, Donghyun Kim

{"title":"Analysis of risk factors for disease progression after salvage radiation therapy with androgen deprivation therapy in prostate cancer patients who have prostate-specific antigen persistence after radical prostatectomy","authors":"Kyeonghyo Lee, Dongchan Kim, J. Nam, D. Park, Wontaek Kim, J. Joo, H. Jeon, Y. Ki, Donghyun Kim","doi":"10.3857/roj.2023.00962","DOIUrl":"https://doi.org/10.3857/roj.2023.00962","url":null,"abstract":"Purpose: To assess risk factors of disease progression after salvage radiation therapy (SRT) with androgen deprivation therapy (ADT) in case of prostate-specific antigen (PSA) persistence after radical prostatectomy (RP). Materials and Methods: We analyzed 57 patients who received SRT with ADT between 2013 and 2019 due to PSA persistence after RP. The endpoint was disease progression defined by biochemical recurrence or clinical recurrence. Age, Pre-RP PSA level, Gleason score, pathologic stage, presence of pelvic lymph node dissection, surgical margins, and PSA at 6-8 weeks after RP were analyzed as predictive factors for disease progression. Kaplan-Meier method and Cox regression models were used for data analysis. Results: At a median follow-up of 38 months (interquartile range, 26–61), 17 patients had disease progression. Pathologic T stage (pT3b vs. pT3a or lower; hazard ratio [HR] = 9.20; p = 0.035) and PSA level at 6-8 weeks after RP (≥2.04 vs. <2.04 ng/mL; HR = 5.85; p = 0.002) were predictors of disease progression. The 5-year disease progression-free survival rate was 46.7% in pT3b group as compared to 92.9 % in pT3a or lower group, and 18.4% for PSA ≥2.04 ng/mL after RP as compared to 79.2% for PSA <2.04 ng/mL. Conclusion: Pathological T stage (pT3b) and post RP PSA ≥2.04 ng/mL are independent risk factors of disease progression after SRT with ADT in patients with PSA persistence after RP.","PeriodicalId":503633,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141386066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Fanconi anemia patient with synchronous esophageal and tongue cancer in COVID-19 era: a case report COVID-19时代范可尼贫血患者同步食管癌和舌癌的治疗：病例报告

Radiation Oncology Journal Pub Date : 2024-01-05 DOI: 10.3857/roj.2023.00654

Tae Hyun Kim, Jin Ho Kim, Chang Hyun Kang, B. Keam, Hak Jae Kim

引用次数: 0